Viatris Inc (VTRS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Viatris Inc Stock (VTRS) Company Profile

Healthcare (1164)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

Nächster Verdiensttermin

Neueste SEC-Einreichungen

VTRS's Discussions on Twitter

Vergleichen Sie VTRS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VTRS Viatris Inc	10.61	11.80B	14.33B	-3.79B	1.84B	-3.17
ZTS Zoetis Inc	151.57	66.38B	9.39B	2.62B	2.22B	5.81
TAK Takeda Pharmaceutical Co Adr	14.76	46.20B	29.96B	957.25M	4.77B	0.304
HLN Haleon Plc Adr	9.685	42.99B	14.26B	1.98B	2.47B	0.4347
TEVA Teva Pharmaceutical Industries Ltd Adr	17.58	19.04B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	309.97	13.63B	2.99B	1.21B	1.13B	25.06

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-06	Eingeleitet	Goldman	Neutral
2024-07-19	Fortgesetzt	Jefferies	Buy
2023-10-23	Herabstufung	BofA Securities	Neutral → Underperform
2023-06-23	Herabstufung	Barclays	Equal Weight → Underweight
2023-04-24	Herabstufung	Barclays	Overweight → Equal Weight
2023-02-17	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2023-01-27	Hochstufung	Jefferies	Hold → Buy
2022-11-10	Hochstufung	UBS	Sell → Neutral
2022-11-08	Hochstufung	Piper Sandler	Underweight → Neutral
2022-10-21	Fortgesetzt	Jefferies	Hold
2022-06-14	Eingeleitet	UBS	Sell
2022-05-10	Herabstufung	Piper Sandler	Neutral → Underweight
2022-03-01	Herabstufung	BofA Securities	Buy → Neutral
2022-03-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-06-15	Eingeleitet	Citigroup	Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2021-03-08	Herabstufung	Goldman	Buy → Neutral
2021-03-02	Herabstufung	JP Morgan	Overweight → Neutral
2021-02-26	Herabstufung	Wolfe Research	Outperform → Peer Perform
2021-01-05	Eingeleitet	Argus	Hold
2020-12-14	Eingeleitet	Bernstein	Mkt Perform

Alle ansehen

Viatris Inc Aktie (VTRS) Neueste Nachrichten

Finanzdaten der Viatris Inc-Aktie (VTRS)

Viatris Inc (VTRS)

Viatris Inc Stock (VTRS) Company Profile

Vergleichen Sie VTRS mit anderen Aktien

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Viatris Inc Aktie (VTRS) Neueste Nachrichten

Trump EO to bolster stockpile of active pharmaceutical ingredients for drugs - Seeking Alpha

Stock Analysis | Viatris OutlookA Bearish Technical Picture Amid Strong Fundamentals - AInvest

Viatris Signals Ongoing Strategic Overhaul, Promises Update In Q3 - insights.citeline.com

Saudi Arabia Generic Drugs Market Outlook Report 2025-2033 | Government Cost-Cutting, Local Manufacturing, and Public Awareness Fuel Rapid Growth - GlobeNewswire Inc.

5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call - FinancialContent

Day 5 of Gains Streak for Viatris Stock with 19% Return (vs. -14% YTD) [8/13/2025] - Trefis

Viatris CEO Smith buys $219k in company stock By Investing.com - Investing.com Nigeria

Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know - TradingView

VTRS Q2 Deep Dive: Pipeline Progress and Cost Discipline Drive Results Amid Industry Headwinds - ca.finance.yahoo.com

Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know - Yahoo Finance

Viatris first to win US approval for generic Venofer - The Pharma Letter

Brufen Maker Viatris Fails To Halt Rival's 'Brisen' TM Quest - Law360

Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals - insights.citeline.com

Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer - MSN

Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. - BioSpace

Why Viatris (VTRS) Is Up 10.3% After Beating Q2 Estimates and Securing FDA Generic Win - simplywall.st

Ampicillin Market Driven by Rising Bacterial Infections - openPR.com

Sector Update: Health Care - MarketScreener

Merz Asks UPC To Bar Viatris Generic MS Drug - Law360

Why Viatris (VTRS) Stock Is Up Today - Yahoo Finance

Viatris Shares Climb Following FDA Clearance of First Generic Iron Sucrose Injection - MSN

Viatris's Generic Iron Sucrose Injection Approval: A Strategic Win for Market Share and Cost-Saving in Healthcare - AInvest

Viatris stock rises after FDA approval of first generic iron sucrose - Investing.com

FDA approves Viatris’ first generic iron sucrose injection for anemia By Investing.com - Investing.com Australia

FDA approves Viatris’ first generic iron sucrose injection for anemia - Investing.com

Viatris announces FDA approval for Iron Sucrose Injection - TipRanks

Carpmaels and A&O Shearman file first SPC suit at UPC for Merz against Viatris - JUVE Patent

Viatris Inc. Reports Strong Q2 2025 Results - TipRanks

Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates - MSN

EpiPen patent expiry opens new era for innovation - MSN

Viatris Earnings Call: Growth Amid Challenges - The Globe and Mail

Viatris aims for top-half 2025 revenue and EPS guidance while advancing late-stage pipeline - MSN

Research Alert: CFRA Keeps Sell Opinion On Shares Of Viatris Inc. - 富途牛牛

Goldman Sachs Adjusts Price Target on Viatris to $11 From $10, Maintains Neutral Rating - MarketScreener

Will Viatris’ (VTRS) Leadership Moves and Steady Outlook Signal Resilience or Ongoing Transition? - simplywall.st

Viatris Inc. (NASDAQ:VTRS) Q2 2025 Earnings Call Transcript - Insider Monkey

Viatris: Q2 Earnings Snapshot - Connecticut Post

Viatris To Seek FDA Approval For MR-141 In Presbyopia In 2H, 2025Did The Stock Catch Your Eye? - RTTNews

Viatris Inc (VTRS) Q2 2025 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges By GuruFocus - Investing.com Canada

Viatris Reports Mixed Q2 Earnings Amid Pipeline Progress and Operational Challenges - AInvest

Viatris 2025 Q2 Earnings Narrowed Losses Amid Revenue Decline - AInvest

Research Alert: Viatris Reports Q2 Top And Bottom-line Beats - 富途牛牛

Viatris Inc. (VTRS) Stock Forecasts - Yahoo Finance

Viatris Earnings: Solid Results Lift Shares, but We Think There Is a Lot More Upward Momentum Left - Morningstar

Divestitures Muddy Viatris' 2025, but New Launches and Pipeline Support Our Outlook - Morningstar

Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise - whbl.com

Viatris Inc. stock rises Thursday, outperforms market - MarketWatch

Viatris' Investment Prospects: Navigating Business Model Concerns and Analyst Expectations - AInvest

Viatris (VTRS) Q2 2025 Earnings Call Transcript - Fortune

Viatris Q2 Revenue Beats Expectations, Stock Surges 5.6% YoY Decline - AInvest

Viatris (NASDAQ:VTRS) Beats Q2 Sales Targets, Stock Soars - TradingView

Finanzdaten der Viatris Inc-Aktie (VTRS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie VTRS